重组新型冠状病毒疫苗（Y25腺病毒载体）(Recombinant Covid-19 vaccine (Shenzhen Kangtai))

概要

基本信息

药物类型

重组载体疫苗、预防性疫苗

别名

KconecaVac

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症

新型冠状病毒感染

非在研适应症-

原研机构

深圳康泰生物制品股份有限公司

在研机构

深圳康泰生物制品股份有限公司

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

印尼 (2021-11-03),

新型冠状病毒感染

最高研发阶段(中国)-

特殊审评紧急使用授权 (印尼)

登录后查看时间轴

关联

1

项与重组新型冠状病毒疫苗（Y25腺病毒载体）相关的临床试验

ChiCTR2100048439

/ Suspended临床1期IIT

A randomized, blinded, placebo-controlled phase I clinical trial to evaluate the safety and tolerability of recombinant novel coronavirus (COVID-19) vaccine (CHO cells) in healthy people aged 3 to 17 years

开始日期1990-01-01

申办/合作机构-

100 项与重组新型冠状病毒疫苗（Y25腺病毒载体）相关的临床结果

登录后查看更多信息

100 项与重组新型冠状病毒疫苗（Y25腺病毒载体）相关的转化医学

登录后查看更多信息

100 项与重组新型冠状病毒疫苗（Y25腺病毒载体）相关的专利（医药）

登录后查看更多信息

1

项与重组新型冠状病毒疫苗（Y25腺病毒载体）相关的文献（医药）

2023-06-01·Data in Brief

Dataset on safety and protective efficacy studies of COVID-19 vaccine candidates based on structurally modified plant virus in female hamsters

Article

作者: Evtushenko, E. A. ; Kondakova, O. A. ; Ryabchevskaya, E. M. ; Karpova, O. V. ; Ivanov, P. A. ; Arkhipenko, M. V. ; Nikitin, N. A. ; Kovalenko, A. O.

This data article is related to the previous research, which addressed the development of a COVID-19 recombinant vaccine candidate. Here, we present the additional data in support of the safety and protective efficacy evaluation of two COVID-19 vaccine candidates based on the coronaviruses' S protein fragments and a structurally modified plant virus - spherical particles. The effectiveness of the experimental vaccines was studied against the SARS-CoV-2 virus in an in vivo infection model in female Syrian hamsters. The body weight of vaccinated laboratory animals was monitored. The histological assessment data of the infected with the SARS-CoV-2 virus hamsters' lungs are provided.

100 项与重组新型冠状病毒疫苗（Y25腺病毒载体）相关的药物交易

登录后查看更多信息